skip to main content

FDA clears new digital treatment for schizophrenia

Research shows the app-based treatment significantly reduces patients’ negative symptoms

APA Style leaf logo Cite This Article in APA Style
American Psychological Association. (2026, October 30). FDA clears new digital treatment for schizophrenia. https://www.apaservices.org/practice/business/technology/on-the-horizon/digital-treatment-schizophrenia

It’s estimated that approximately 27 million people are living with schizophrenia worldwideopens in new window. Schizophrenia is characterized by a variety of symptoms that can include hallucinations, delusions, disorganized thinking and behavior, as well as “negative symptoms” such as limited speech, diminished emotional expression, anhedonia, and social withdrawal. Schizophrenia is also associated with significant distress and impairments in daily living; while treatments exist—such as medication, psychoeducation, family interventions, CBT, and life skills training—not all interventions work equally well for all symptoms. For example, negative symptoms often have a limited response to existing medications, and while psychosocial interventions show benefits, care remains difficult to access. Additionally, people living with schizophrenia report a desire for more treatments that target negative symptoms and increase quality of life.opens in new window

There has been growing interest in using digital tools to help treat schizophrenia, as they can provide a flexible option for individuals to integrate into their daily lives. Recently, the FDA cleared the digital therapeutic, Motivistaopens in new window, for the treatment of negative symptoms of schizophrenia for adults (age 18 and older) as an adjunctive intervention to outpatient care. Motivista is an app that delivers a 16-week intervention that uses CBT techniques—including behavioral activation, cognitive restructuring, social skills training, positive affect training, and distress tolerance skills—to help individuals work toward personalized goals. Treatment is structured in three phases: orientation, goal attainment, and consolidation and is delivered using a variety of lessons, activities, daily check-ins, and personalized messages.

Motivista was evaluated in a recent randomized controlled trial. In the trial, 457 participants with negative symptoms of schizophrenia across 66 clinical sites were randomly assigned to use Motivista (n=227) or a psychoeducational app (n=230). Participants were assessed for clinical symptoms using the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure subscale (CAINS-MAP) at the outset and conclusion of the study (16 weeks). Results revealed that individuals who received treatment with Motivista had a significant reduction in negative symptoms at the conclusion of the study compared with individuals in the control group.

Additionally, daily engagement was high and while a small number of serious adverse effects occurred (three in the Motivista group and five in the control group), these were determined to be unrelated to participation in the study. Based on these findings, the researchers concluded that Motivista appears to be an effective and well tolerated treatmentopens in new window for individuals with schizophrenia.

Click Therapeutics, the maker of Motivista, reports that they are working on additional research investigating the potential sustained benefit of the treatmentopens in new window. They are also working with payers, providers, and community organizations to make the treatment available to those who may benefit from it.

Related and recent